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A B S T R A C T
Inflammation is a major cause of morbidity and mortality in Western societies. Despite use of multiple drugs,
both chronic and acute inflammation still represent major health burdens. Inflammation produces highly re-
active dicarbonyl lipid peroxidation products such as isolevuglandins which covalently modify and cross-link
proteins via lysine residues. Mitochondrial dysfunction has been associated with inflammation; however, its
molecular mechanisms and pathophysiological role are still obscure. We hypothesized that inflammation-in-
duced isolevuglandins contribute to mitochondrial dysfunction and mortality. To test this hypothesis, we have
(a) investigated the mitochondrial dysfunction in response to synthetic 15-E2-isolevuglandin (IsoLG) and its
adducts; (b) developed a new mitochondria-targeted scavenger of isolevuglandins by conjugating 2-hydro-
xybenzylamine to the lipophilic cation triphenylphosphonium, (4-(4-aminomethyl)-3-hydroxyphenoxy)butyl)-
triphenylphosphonium (mito2HOBA); (c) tested if mito2HOBA protects from mitochondrial dysfunction and
mortality using a lipopolysaccharide model of inflammation. Acute exposure to either IsoLG or IsoLG adducts
with lysine, ethanolamine or phosphatidylethanolamine inhibits mitochondrial respiration and attenuates
Complex I activity. Complex II function was much more resistant to IsoLG. We confirmed that mito2HOBA
markedly accumulates in isolated mitochondria and it is highly reactive with IsoLGs. To test the role of mi-
tochondrial IsoLGs, we studied the therapeutic potential of mito2HOBA in lipopolysaccharide mouse model of
sepsis. Mito2HOBA supplementation in drinking water (0.1 g/L) to lipopolysaccharide treated mice increased
survival by 3-fold, improved complex I-mediated respiration, and histopathological analyses supported
mito2HOBA-mediated protection of renal cortex from cell injury. These data support the role of mitochondrial
IsoLG in mitochondrial dysfunction and inflammation. We conclude that reducing mitochondrial IsoLGs may be
a promising therapeutic target in inflammation and conditions associated with mitochondrial oxidative stress
and dysfunction.
1. Introduction
Inflammation is implicated in many diseases that represent major
causes of morbidity and mortality in Western societies including car-
diovascular diseases, acute kidney injury, and lung and heart failure,
[1]. Despite use of multiple drugs, both chronic and acute inflammation
still represent major health burdens. In the recent years, it has become
clear that oxidative stress plays an important role in pathophysiology of
many conditions associated with inflammation such as cardiovascular
diseases and sepsis [1,2]. Increased lipid peroxidation [3] has been
shown in hypertension, atherosclerosis and sepsis, using the clinically
validated marker F2-isoprostanes [4]. Lipid peroxidation via the iso-
prostane pathway produces a family of highly reactive γ-ketoaldehydes,
the isolevuglandins (IsoLGs) [5], which rapidly react with primary
amines and causes cellular dysfunction [6]. IsoLGs covalently modify
and cross-link proteins by reacting with their lysine residues, and this
modification can directly inhibit enzymatic functions, induce in-
flammation and cause cytotoxic effects [6,7]. IsoLGs have been im-
plicated in pro-inflammatory dendritic and T cell activation in hy-
pertension [8]. Acute treatment of isolated mitochondria with IsoLG
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disrupts mitochondrial respiration and promotes mitochondrial per-
meability transition pore (mPTP) opening [9], however, the role of
mitochondrial IsoLGs in pathological conditions has not been in-
vestigated.
Sepsis causes devastating multi-organ failure such as acute kidney
injury [10] which is linked with increased oxidative stress and mi-
tochondrial dysfunction. Levels of IsoLG adducts are elevated in ex-
perimental models of sepsis [11]. Inflammation has been associated
with mitochondrial dysfunction; however, its pathophysiological role
and molecular mechanisms are still obscure. Mitochondria are one of
the major sources of free radicals [12] that can potentially produce
IsoLG. Given the potential highly injurious nature of IsoLGs, we propose
that inflammation-induced IsoLGs plays an important role in mi-
tochondrial dysfunction.
Although oxidative stress is common in multiple pathological con-
ditions [13], antioxidant therapy is not currently available and common
antioxidants like ascorbate and vitamin E are ineffective in the clinical
studies [14]. These agents unlikely reach important sites of free radical
production such as mitochondria. Furthermore, antioxidants can po-
tentially interfere with redox signaling increasing inflammation and
tissue injury due to increased cytokine production and suppression of
Nrf2 signaling [15,16].
Oxidative stress in aging and inflammation results in increased
peroxidative damages to polyunsaturated fatty acids (PUFA). The cause
of the isoprostane type of lipid peroxidation remained unclear. It has
been proposed that autoxidation of PUFA can be initiated by perhy-
droxyl radical (HO2•) [17,18], a protonated form of superoxide radical,
which is produced in mitochondria. Hypoxia and acidification of a
tissue increase production of HO2• [17]. We propose that accumulation
of the oxidatively damaged mitochondrial phospholipids and IsoLG
adducts is the result of PUFA oxidation by mitochondrial HO2•. The
HO2• hypothesis of the isoprostane lipid peroxidation agrees with the
known fact that classical antioxidants are ineffective in prevention of
this type oxidative stress and aging [19]. Isoprostane lipid peroxidation
produces racemic mixture of various forms of isoprostanes and iso-
levuglandins [5]. Some of the isoprostanes can be responsible for in-
itiation of the inflammatory responses directly [4,20] while reactive
IsoLG produces cytotoxic and immunogenic IsoLG-lactam adducts [7].
Production of IsoLG is one of the common downstream products of
oxidative stress [7,21] and scavenging IsoLG with 2-hydro-
xybenzylamine (which is not an antioxidant) reduces endothelial dys-
function, diminishes fibrosis and attenuates hypertension [8,22].
Therapies specifically targeted at mitochondria represent promising
strategies to reduce target-organ-damage [23,24]. We hypothesized
that mitochondrial targeting of the IsoLG scavenger 2-hydro-
xybenzylamine [8], by conjugating it with the lipophilic cation tri-
phenylphosphonium [25], would reduce mitochondrial dysfunction
and attenuate mortality associated with sepsis. In this work, we studied
(a) mitochondrial dysfunction in response to synthetic IsoLG and its
adducts, (b) developed new mitochondria-targeted IsoLG scavenger
mito2HOBA, and (c) tested if mito2HOBA protects from mitochondrial
dysfunction and mortality in lipopolysaccharide (LPS) model of sepsis.
2. Materials and methods
2.1. Reagents
LPS was obtained from Sigma (St Louis, MO). 2-
Hydroxybenzylamine (2HOBA) and its non-scavenger analog 4-hydro-
xybenzylamine (4HOBA) were prepared as described previously [26].
15-E2-IsoLG was synthesized by the method of Amarnath et al. [27] and
kept in DMSO stock solution at −80 °C. All other reagents were from
Sigma (St Louis, MO).
2.2. Animal experiments
All experimental procedures were approved by Vanderbilt and
Mercer Institutional Animal Care and Use Committees. The use of LPS is
well-established model of bacterial sepsis in rodents (1–3). The con-
centrations of LPS that can be used to induce sepsis in mice depend on
many factors (source of LPS, age/size, and strains of animals, desired
time of response, target of interest, etc.) and may vary between dif-
ferent manufactures [28]. To test the protective properties of mito2-
HOBA, we used LPS from E. coli O111:B4 (Sigma L8274) in our studies.
The lot of LPS tested in preliminary studies had a LD50 of 25 μg/g at
24 h post-injection. The same lot of LPS was used throughout entire
study.
Forty C57BL/6J 3-month old mice were equally divided in four
groups: Sham (Control), LPS-injected mice (LPS), mice supplemented
with mito2HOBA (0.1 g/Liter) in the drinking water (mito2HOBA), and
LPS-injected mice pretreated with mito2HOBA in the drinking water
(LPS + mito2HOBA). Sepsis-induced mortality among animals was
used to evaluate the protective role of mito2HOBA. Mortality was as-
sessed regularly several times per day for three consecutive days. In
additional experiments mice were sacrificed after 24 h of LPS injection
to analyze mitochondrial complex I and complex II activities.
2.3. Mitochondrial studies
All procedures for mitochondrial isolation, respiration analysis and
respiratory chain enzymology have been previously described [29,30].
Mitochondrial complex I and complex II activities were evaluated after
24 h of LPS injection as described above. Mitochondria were isolated
from 12 to 14-week-old male C57BL6/6J mouse kidneys. For respira-
tion studies, electrons were entered at either complex I (gluta-
mate + malate as substrate) or complex II (succinate as substrate).
Mitochondria in some organs, e.g. brain, oxidize up to 50% of pyruvate
and glutamate via transamination to α-ketoglutarate and further con-
version to succinate [31]. Since kidney mitochondria are much less
studied than mitochondria from other organs, we used the specific in-
hibitor of Complex II malonate (5 mM) to evaluate the alternative
pathways for glutamate oxidation. The Complex II mediated respiration
was defined as malonate-inhibited oxygen consumption while Complex
I specific respiration was defined as malonate resistant oxygen con-
sumption.
Respiration rates were measured using Fluorescence Lifetime Micro
Abbreviations
IsoLG isolevuglandins (aka isoketals)
PE phosphatidylethanolamine
15-E2-IsoLG 15-E2 stereoisomer of isolevuglandins
15-E2-IsoLG-PE adduct of PE with 15-E2-IsoLG stereoisomer
2HOBA 2-hydroxybenzylamine
4HOBA non-scavenger analog of 2HOBA, 4-hydroxybenzylamine
mito2HOBA conjugate of 2-hydroxybenzylamine to lipophilic ca-
tion triphenylphosphonium, (4-(4-aminomethyl)-3-
hydroxyphenoxy)butyl)-triphenylphosphonium
mitoTEMPO (2-(2,2,6,6-tetramethylpiperidin-1-oxyl-4-ylamino)-2-
oxoethyl) triphenylphosphonium
mPTP mitochondrial permeability transition pore
PUFA polyunsaturated fatty acids
ROS reactive oxygen species
LPS Lipopolysaccharide
WT wild-type C57BL/6J mice
SMP submitochondrial particles
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Oxygen Monitoring System (Instech Laboratories, Inc.). Two oxygen
consumption rate measurements were performed for each substrate and
each run included additions of 0.24mg/ml protein, ADP (125 μM) to
stimulate state III and subsequent state IV respiration. OXPHOS specific
enzyme activities in submitochondrial particles (SMP) were measured
using a Varian Cary 300 Bio UV/Vis spectrophotometer with tem-
perature controlling cell holder. Briefly, SMP were prepared by soni-
cation of isolated organelles. Complex I activity was monitored in tri-
plicate samples as the reduction of 10 μM decylubiquinone at 272 nm
by 15 μg of mitochondrial protein with 40 μM NADH. Using this
method, 90–100% of the total complex I activity is sensitive to rotenone
inhibition. Complex II activity was measured by monitoring the ab-
sorbance at 600 nm during the oxidation of 50 μM DCPIP as artificial
electron acceptor by 65 μM ubiquinone in presence of 2mM KCN and
2 μg/ml rotenone and antimycin A.
2.4. Analysis of complex I and complex II mediated respiration in kidney
mitochondria
In order to define specific alterations in the mitochondrial respira-
tion in LPS model of sepsis and test the potential protection by
mito2HOBA we have adopted the Seahorse protocol for mitochondrial
studies [32] in the presence of mitochondrial substrates Gluta-
mate + Malate (GM) or succinate. To define the specific role of com-
plex I mediated respiration we performed measurements in the pre-
sence of complex II inhibitor malonate (5 mM). We have measured
basal respiration in the presence of mitochondria plus substrates, cou-
pled respiration after addition of ADP (2 mM), proton leak following
addition of oligomycin A (2.5 μM), uncoupled respiration after sup-
plementation of CCCP (1 μM), and non-mitochondrial respiration with
mixture of antimycin A and rotenone (1 μM) [32]. Mitochondrial stu-
dies where independently verified in two labs using Oroboros O2k high-
resolution respirometry and Fluorescence Lifetime Micro Oxygen
Monitoring System (Instech Laboratories, Inc). Kidney mitochondria
were isolated from control sham mice, LPS-injected mice (25 μg/g, 16 h
post-injection), mito2HOBA supplemented mice (0.1 g/Liter drinking
water, 4 days), or mito2HOBA plus LPS (0.1 g/Liter mito2HOBA for 3
days plus LPS injection). One kidney was used for mitochondrial studies
and second kidney was used for histopathological studies.
2.5. Kidney histological analyses
Kidneys were harvested from mice and placed immediately in 10%
formalin. Following fixation, kidneys were washed with saline, placed
in 70% ethanol, and processed in the following sequence: 70% ethanol;
80% ethanol; 95% ethanol; 100% ethanol; 100% xylene. Then kidneys
were embedded in POLY/Fin paraffin (ThermoFisher). Five-μm sections
were cut using a Leitz 1512 microtome and were mounted on glass
slides. Sections were stained with hematoxylin and eosin and were
viewed using an Olympus IX70 microscope. Images were captured with
a Jenoptix Progress C12 digital camera. Histopathological scores of
kidneys were measured as follows: (0) No tubular injury; (1)< 10%
tubules injured; (2) 10–25% tubules injured; (3) 25–50% tubules in-
jured; (4) 50–75% tubules injured; (5) > 75% tubules injured [33].
2.6. Synthesis of mitochondria-targeted IsoLG scavenger mito2HOBA (Fig.
figs1)
Cesium carbonate (4.9 g, 15mmol) was added to 2,4-dihydrox-
ybenzaldehyde (4.2 g, 30mmol) and 1,4-dibromobutane (6.6 g,
30mmol) in acetonitrile (50ml). The mixture was heated at 80 °C under
argon for 5 h, cooled and added to 1M phosphate buffer, pH 7 (30ml),
ice and KH2PO4 (2 g) with mixing. The solid was removed by filtration
and the filtrate was extracted with ethyl acetate. Purification by column
(silica, 9:1 hexane-ethyl acetate) yielded 4-(4-bromobutoxy)-2-hydro-
xybenzaldehyde (4.1 g, 50%). It was mixed with triphenylphosphene
(4.2 g) in toluene (75ml) and refluxed under argon for 15 h. The pink
solid was purified by flash chromatography (0–10% methanol in di-
chloromethane to get 4-(4-formyl-3-hydroxyphenoxy)butyl)triphenyl-
phosphonium bromide (4.8 g, 60%). The aldehyde was converted to
oxime by stirring with NH2OH·HCl (0.63 g) and CH3CO2Na (0.74 g) in
ethanol (40ml) for 1 h. The crude product (5.6 g) was dissolved in
Fig. 1. Acute treatment with IsoLG or IsoLG-PE impairs mitochondrial respiration. (A) Intact mouse kidney mitochondria were incubated (5min) with ethanol as
vehicle (Sham), IsoLG (20 μM) or IsoLG-PE (20 μM) and then diluted with respiration buffer 20-fold prior to addition of Glutamate and Malate, ADP (50 μM) and
measurements of oxygen consumption in State III. *P < 0.001 vs Sham, **P < 0.03 vs IsoLG. (B) Oxygen consumption in the presence of complex I substrates
Glutamate + Malate and ADP (State III) and Respiratory Control Ratio (State III/State IV, %) in intact kidney mitochondria treated with vehicle, IsoLG (1.5 μM) or
IsoLG-PE (1.5 μM) in the respiration chamber. (C) State III respiration and Respiratory Control Ratio (State III/State IV, %) in presence of complex II substrate
Succinate and ADP following addition of vehicle, IsoLG (1.5 μM) or IsoLG-PE (1.5 μM) in the respiration chamber. Data are expressed as mean ± STD (N = 4–6).
*P < 0.01 vs Vehicle.
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acetic acid (60ml). Zinc powder (6 g) was added and the suspension
was heated in a water bath (60 °C) for 1 h. The mixture was cooled,
filtered through Celite. The filtrate was evaporated and co-evaporated
with toluene (3× 10ml) and ethanol (15mL). The residue was heated
in hot 2-propanol (200ml), filtered and cooled to obtain pure
mito2HOBA; 3.0 g; MS m/z 456 (M+).
Statistics. Data were analyzed using the Student-Neuman-Keuls post-
hoc test and analysis of variance (ANOVA). P levels< 0.05 were con-
sidered significant.
3. Results
3.1. Isolevuglandins impaired mitochondrial respiration
Complex I is a key component of mitochondrial oxidative phos-
phorylation. Inactivation of complex I can lead to reduced ATP pro-
duction and tissue damage. Addition of IsoLG to cells produces both
protein-adducts and IsoLG-phosphatidylethanolamine adducts (IsoLG-
PE) which can independently contribute to mitochondrial dysfunction.
We tested whether IsoLG or IsoLG-PE could contribute to mitochondrial
dysfunction. Five-minute treatment of isolated mitochondria with 15-
E2-IsoLG-PE (20 μM) inhibited state 3 respiration by 41% while similar
doses of 15-E2-IsoLG reduced state 3 respiration by 74% in the presence
of complex I substrates glutamate + malate (Fig. 1A). These data
support the potential role of IsoLG-PE and IsoLG-protein adducts in
mitochondrial dysfunction. To further define the potential targets of
IsoLG in mitochondria, we studied the effect of IsoLG and IsoLG-PE on
complex I- and complex II-mediated respiration. Acute addition of a low
dose of 15-E2-IsoLG (0.5 μM) significantly attenuated complex I-medi-
ated respiration, but complex II respiration was much less affected
(Fig. 1B and C). Treatment of intact mitochondria with a low dose of
15-E2-IsoLG-PE partially diminished complex I respiration but did not
affect complex II respiration. These data directly demonstrate the im-
pairment of mitochondrial respiration by IsoLG and IsoLG-PE.
3.2. IsoLG and IsoLG adducts inhibit complex I activity
We have hypothesized that IsoLG can directly affect the complex I
and complex II activity. To test this hypothesis, we studied the activity
of complex I and complex II in mitochondrial lysates treated with a
bolus of IsoLG. It was found that IsoLG causes robust complex I in-
activation by 74% while complex II activity was inhibited by only 21%
(Fig. 2A). These data showed that complex I respiration is particularly
sensitive to IsoLG.
As shown above, both IsoLG and IsoLG-PE diminish complex I-
mediated respiration, therefore, complex I could be affected by IsoLG
directly or inhibited by low-molecular IsoLG adducts. We tested the
inhibition of complex I by IsoLG adducts compared with bolus IsoLG.
Supplementation with IsoLG modified-ethanolamine (IsoLG-ETN),
modified L-Lysine (IsoLG-Lys), or modified-PE (IsoLG-PE) inhibited
complex I activity by more than 80%, similar to the effect of bolus
IsoLG (Fig. 2B). Interestingly, IsoLG modified spermine (IsoLG-sper-
mine) did not affect complex I, suggesting that natural poly-amines
could potentially protect complex I from IsoLG mediated inhibition.
These data demonstrate that complex I is directly inhibited by low-
molecular IsoLG adducts such as IsoLG-Lys and IsoLG-PE; thus, these
adducts may mediate the impairment of complex I induced by direct
addition of IsoLG. These data directly confirm that IsoLG-mediated
inhibition of complex I contribute to mitochondrial dysfunction.
3.3. Mitochondria-targeted IsoLG scavenger mito2HOBA
To test the hypothesis that specific scavenging of IsoLG in mi-
tochondria improves mitochondrial function, we developed a
Fig. 2. Inhibition of complex I and complex II activity by IsoLG and IsoLG-adducts. (A, B) Mouse kidney mitochondrial lysate was incubated with DMSO (vehicle) or
IsoLG for 5-minites prior to analysis of complex I or complex II activity as described previously [29,30]. *P < 0.01 vs Sham. **P < 0.05 vs Sham. (C) Mouse kidney
mitochondrial lysate was acutely treated with DMSO (Control), ethanolamine, spermine, L-lysine, IsoLG (1.5 μM) or IsoLG modified-ethanolamine (IsoLG-ETN,
1.5 μM), -spermine (IsoLG-Sper, 1.5 μM), L-lysine (IsoLG-Lys, 1.5 μM), -phosphatidylethanolamine (IsoLG-PE, 1.5 μM) prior to measurements of complex I activity
expressed as a % of Control (100%). Data are expressed as mean ± STD (N = 3–6). *P < 0.001 vs Sham, #P < 0.01 vs IsoLG.
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mitochondrial-targeted IsoLG scavenger, mito2HOBA, by conjugating
the lipophilic cation triphenylphosphonium to 2-hydroxybenzylamine
(Fig. 3). The membrane potential of mitochondria within living cells is
negative inside (−150mV). As this membrane potential is much higher
than in other organelles within cells, lipophilic cations such as triphe-
nylphosphonium selectively accumulate within mitochondria [34].
Molecules conjugated to triphenylphosphonium are therefore targeted
to the mitochondria [25]. For example, mitoTEMPO is concentrated
within the mitochondrial matrix by more than a five hundred-fold
[35,36].
Mito2HOBA is a water-soluble compound which can be supplied in
the media and provided to animals in the drinking water. In our animal
experiments, mito2HOBA was well tolerated in doses from 0.1 to 0.3 g/
L. Mass spectrometric analysis of kidney and heart mitochondria iso-
lated from mice that received mito2HOBA in their drinking water
(0.1 g/L) for 5-days confirmed that mito2HOBA predominantly accu-
mulated in the mitochondrial fraction (by 80%) at μM levels. Likewise,
incubation of isolated mitochondria with mito2HOBA (0.1 μM) causes
robust accumulation of mito2HOBA in the mitochondrial pellet by 400
to 600-fold (Fig. 3).
In order to confirm the IsoLG scavenging properties of mito2HOBA,
we studied its reaction with the IsoLG analog 4-oxopentanal as we
described previously [26]. Mito2HOBA was highly reactive with 4-ox-
opentanal with a reaction rate constant that was about 50% of 2HOBA
itself (Supplemental Fig. 1S). The slightly reduced reaction rate may be
due to steric hindrance by the bulky triphenylphosphonium group. The
overall rate of IsoLG scavenging in physiological conditions depends
both on the rate constant and the local concentration of the scavenger
(V = k*[mito2HOBA]*[IsoLG]). Of note, 2HOBA analogs do not sca-
venge oxidants such as O2• and peroxynitrite [8]. We hypothesized that
supplementation with mito2HOBA at low submicromolar level would
result in low cytoplasmic level but significant mitochondrial accumu-
lation (Fig. 3) as we had previously described for mitochondria-targeted
mitoTEMPO [36]. This will result in low level of mito2HOBA in cyto-
plasm but high mitochondrial accumulation leading to specific
scavenging of IsoLG in mitochondria (Fig. 3).
3.4. Complex I- and complex II-mediated kidney respiration in LPS and
mito2HOBA treated mice
The kidney has a high demand for energy and renal mitochondria
can potentially oxidize glutamate via transamination to α-ketoglutarate
and further conversion to succinate [31]. We analyzed mitochondrial
respiration in the presence of Glutamate + Malate (GM), succinate and
used Complex II inhibitor malonate to measure the specific Complex I
mediated respiration. Malonate inhibited 58% of glutamate-driven re-
spiration (Fig. 4A) supporting the metabolic plasticity of renal mi-
tochondria. Interestingly, LPS injection reduced both GM- and succi-
nate-mediated respiration, and substantially diminished complex I-
specific oxygen consumption in the presence of GM + malonate
(Fig. 4B). LPS significantly increased mitochondrial protein leak with
both substrates indicating uncoupling of mitochondrial respiration.
Mito2HOBA alone slightly reduced succinate-driven respiration and
improved complex I-specific oxygen consumption in the presence of
GM + malonate (Fig. 4C). Furthermore, mito2HOBA supplementation
significantly protected from LPS-induced impairment of GM-mediated
respiration and complex I-specific oxygen consumption in the presence
of GM+malonate but did not affect the succinate mediated respiration
or mitochondrial protein leak (Fig. 4D).
3.5. Mito2HOBA reduces mitochondrial dysfunction and attenuates
mortality in LPS model of sepsis
To test the role of IsoLG-mediated mitochondrial dysfunction we
supplemented mice with novel mitochondria-targeted IsoLG scavenger
mito2HOBA (0.1 g/L). Treatment with LPS (25 μg/g by body weight)
caused severe mortality but treatment with mitochondria-targeted
IsoLG scavenger mito2HOBA increased animal survival at 96 h post-
injection by 3-fold (Fig. 5A). Additional studies showed that complex I/
complex II activity ratio was markedly decreased in mitochondria iso-
lated from the kidneys of LPS-treated mice compared to vehicle treated
mice (Fig. 5B). Supplementation of mice with mito2HOBA completely
preserved the complex I/complex II activity ratio even after LPS
treatment. These data support the role of mitochondrial IsoLG in the
mitochondrial dysfunction and mortality associated with sepsis.
Fig. 3. Mitochondria-targeting of IsoLG scavenger mito2HOBA. Linking the 2-hydroxybenzylamine to lipophilic cation triphenylphosphonium directs mito2HOBA to
mitochondria since its membrane potential is much higher than in other organelles within cells leading to selective accumulation within mitochondria [34].
Inflammation and oxidative stress oxidizes arachidonic acid to reactive IsoLG which react rapidly with protein lysine residues and phosphatidylethanolamine
yielding cytotoxic IsoLG adducts [6]. Incubation of mito2HOBA (0.1 μM) with isolated mitochondria (1 mg/ml) causes robust accumulation of mito2HOBA in the
mitochondrial fractions. Data are expressed as mean ± STD (N=4). Mitochondria-targeted mito2HOBA can potentially reduce mitochondrial dysfunction by
scavenging of IsoLG in the mitochondrial matrix.
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3.6. Mito2HOBA protects against LPS-induced renal injury
Histological analyses of kidneys were performed to provide visual
evidence of mito2HOBA protection (Fig. 6). The cortex and medulla of
control kidneys appeared normal with no evidence of injury. In con-
trast, kidneys of mice treated with LPS demonstrated significant cellular
injury. Numerous areas of vacuolization and cellular degeneration
(arrows) were identified in the cortex and medulla of kidneys from LPS-
injected mice. In the medulla, numerous proximal tubules stained ba-
sophilic (arrowheads) suggesting alterations in intracellular metabolic
processes. Similar to control mice, kidneys of mice supplemented with
mito2HOBA appeared normal. A few small areas of cellular degenera-
tion were scattered sparsely throughout the medulla (not pictured).
When mice were treated with LPS plus mito2HOBA, the cortex ap-
peared normal while cellular injury was evident in the renal medulla.
Small areas of cellular degeneration and basophilic staining were ob-
served throughout the medulla, but the extent and degree of injury was
less than that in kidneys of mice treated with LPS alone. As shown
quantitatively in Fig. 5C, mito2HOBA appeared to be protective against
LPS-induced cellular injury.
4. Discussion
In this work we show that IsoLG or its stable adduct IsoLG-PE impair
mitochondrial respiration, particularly complex I-mediated respiration
in the presence of malate and glutamate (Fig. 1). Our experiments in
mitochondrial lysates show that IsoLG and IsoLG adducts specifically
inhibited complex I activity (Fig. 2). Furthermore, we showed that a
mitochondria-targeted form of a known IsoLG scavenger 2HOBA
(Fig. 3) markedly protected against renal injury and animal mortality in
LPS-induced sepsis model (Figs. 5 and 6).
Impaired oxidative phosphorylation significantly contribute to
organ damage in sepsis [37]. Mitochondrial dysfunction in sepsis was
recently linked to complex I damage, and targeted protection of com-
plex I was proposed as a treatment for sepsis [38]. Sepsis was previously
shown to increase IsoLG production [11] and IsoLG can induce the
mitochondrial permeability transition [9]. We hypothesized that IsoLG
might also mediate the mitochondrial dysfunction found in sepsis. In-
deed, our data indicates that complex I activity is particularly sensitive
to IsoLG and IsoLG adducts suggesting that sepsis-induced IsoLG likely
inhibits complex I activity to promote mitochondrial dysfunction.
Consequently, this pathway may be important for the multi-organ
failure induced by sepsis [39].
It is well known that with NADH and the NAD-dependent substrates
the rate of respiration is limited by the FAD-dependent NADH dehy-
drogenase of Complex I. Therefore, all downstream sites of the re-
spiratory chain remain oxidized and produce very little reactive oxygen
species [40]. Organs requiring fast ATP production use oxidation of
succinate produced via transamination of pyruvate or glutamate in
order to accelerate the rates of mitochondrial respiration and ATP
production. We have previously shown that brain mitochondria utilize
this pathway, and now we show for the first time that kidney mi-
tochondria also adopt to high energy demands by diverting the mi-
tochondrial metabolite flux to succinate to feed the Complex II medi-
ated respiration. Complex II is a much simpler protein and it has higher
abundance compared to Complex I [41]. Interestingly, it is seemingly
much less sensitive to the damaging effects of inflammation in the LPS
model (Figs. 4 and 5). Meanwhile, it must be noted that higher
Fig. 4. Respiration of kidney mitochondria isolated from control sham, mito2HOBA-supplemented, LPS treated and LPS plus mito2HOBA mice. To study the
mitochondrial function, the combination of glutamate and malate (GM) or succinate was used as substrates. Since glutamate can be converted via transamination to
α-ketoglutarate and further to succinate [31], we used complex II inhibitor malonate to define specific complex I respiration. The basal respiration (1) was measured
in mitochondria supplemented with respiratory substrates. Then ADP was added to measure the coupled respiration (2). The proton leak (3) was determined after
addition of complex V inhibitor oligomycin A. The uncoupled respiration (4) was measured after supplementation with CCCP. Finally, antimycin A plus rotenone
were added to assess non‐mitochondrial respiration (5) as described previously [32]. Data are mean ± STD (n = 4–6). *P < 0.001 vs GM, #P < 0.01 vs Control,
§P < 0.001 vs Control, **P < 0.01 vs LPS.
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respiration rate by Complex II has substantial pitfalls since it drives
overproduction of mitochondrial reactive oxygen species via reverse
electron transport [31,42]. The succinate mediated oxidant production
contributes to brain and heart injury, and succinate-driven reverse
electron transport has been proposed as a new therapeutic target
[43,44]. Our data suggest that LPS induces switch from complex I to
complex II respiration, however, this maladaptation can promote
kidney damage and inflammation similarly to the previously reported
succinate driven cardiac injury [44,45]. Analysis of specific substrate
utilization showed significant decrease in complex I, II and IV and fatty
acid-mediated respiration in kidney mitochondria in LPS-induced sepsis
[46]. Our data suggest that mito2HOBA protects mitochondria and
reduces cellular injury; however, the specific targets of mitochondrial
IsoLG remain elusive. IsoLG can potentially attenuate functions of
multiple mitochondrial complexes and diminish mitochondrial meta-
bolism of fatty acids. Further studies are warranted to elucidate the
specific pathophysiological role of mitochondrial IsoLG. Sepsis induces
kidney inflammation, renal tubular cell injury, apoptosis and mi-
tochondrial swelling [46,47] and treatment with mitochondria-targeted
inhibitor of lipid oxidation, SS-31 [48], reduces sepsis-induced organ
dysfunctions [49]. Our data support the protective effect of mito2HOBA
from pathological alterations in sepsis [50].
Fig. 5. Animal survival (A), Complex I/Complex II activity ratio (B) and (C) histopathological scores in Control, mito2HOBA-supplemented and LPS treated mice.
Three months old C57BL/6J mice (25–28 g) were supplemented with mito2HOBA (drinking water, 0.1 g/L) for 72 h prior to LPS injection (25 μg/g). Complex I/
Complex II activity ratio is expressed as a % compared to Control (100%). (C) Histopathological scores of renal injuries as described in methods section. Quantitative
analysis of cellular injury shows that treatment with mito2HOBA leads to a significant reduction in cellular injury compared with treatment with LPS alone. Data are
mean ± STD *P < 0.01 vs LPS (n = 6), *P < 0.01 vs LPS (n = 10).
Fig. 6. Histological analysis of cellular injury in kidneys of control, mito2HOBA supplemented, LPS-injected and LPS + mito2HOBA-treated mice. Representative
sections from control mice show normal glomeruli (g), proximal tubules (P), and distal tubules (*) in the cortex (A) and medulla (B). Sections of kidney from mice
treated with mito2HOBA alone (C & D) were very similar to those from control mice. While most tubules appeared normal, a small number of proximal tubular cells
in the medulla (D) showed slight evidence of cytoplasmic vacuolization. There was no evidence of injury in the cortex (C). In contrast, sections of kidney from mice
treated with LPS show vacuolization and cellular degeneration (arrows) in the cortex (E) and medulla (F). In the medulla, numerous proximal tubular cells stained
basophilic (arrowheads) suggesting alterations in intracellular metabolism. Distal tubules (*) appeared normal. When mice were treated with LPS and mito2HOBA,
cellular injury was detected in medulla (H) while the cortex (G) appeared normal. The overall injury was greatly reduced compared with that of mice treated with
LPS. In the medulla, small areas of cytoplasmic degeneration (arrows) and basophilic staining (arrowheads) were evident. Scale bar = 50 μm.
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Mitochondrial dysfunction in sepsis was recently linked to complex I
damage and targeting complex I was proposed in sepsis [38]. In this
work we have demonstrated the potential role of IsoLGs and IsoLG
adducts in inhibition of complex I and therapeutic effect of mito2HOBA
on complex I function. We propose to target the mitochondrial IsoLGs
to improve the mitochondrial respiration and rescue from mitochon-
drial dysfunction in conditions associated with inflammatory injury.
To test the potential role of IsoLG in inflammation-induced mi-
tochondrial dysfunction, we developed the mitochondria-targeted
IsoLG scavenger mito2HOBA. Driven by its lipophilic triphenylpho-
sphonium moiety, mito2HOBA robustly accumulated in the mitochon-
dria of multiple organs such as kidney, heart and liver. At 0.1 g/L in
drinking water, mito2HOBA was well tolerated by mice. Mito2HOBA
showed significant protective effects in the LPS model of sepsis. Indeed,
mito2HOBA supplementation reduces animal immediate and extended
mortality by 3-fold and mito2HOBA completely preserves complex I/
complex II activity ratio in LPS-treated mice. Treatment with
mito2HOBA also eliminated injury to tubules in the renal cortex and
significantly reduced cellular degeneration and injury in medullary
tubules. The rapid effect of mito2HOBA could potentially improve
outcomes in the clinical settings, as it can give additional time for
medical personnel to perform additional live-saving procedures for
septic patients. Overall, these data support the role of mitochondrial
IsoLG in mitochondrial dysfunction and therapeutic potential of mi-
tochondria-targeted IsoLG scavenger mito2HOBA.
Our work also suggests that targeting mitochondrial IsoLG may be
more effective than simply targeting mitochondrial ROS production.
Kozlov and colleagues proposed that mitochondrial ROS accelerates
inflammatory response and promotes the end-organ-damage, so tar-
geting of mitochondrial ROS would be an effective treatment for in-
flammation [24]. Indeed, treatment of LPS-treated rats with the mi-
tochondria-targeted antioxidants mitoTEMPO and SkQ1 reduced the
expression of inducible nitric oxide synthase and diminished markers of
organ damage [24]. However, these mitochondria-targeted anti-
oxidants also increased the markers of organ damage at earlier time
points suggesting the potential interference of the antioxidants with cell
signaling needed to activate protective responses. Furthermore, recent
studies of cecal ligation and puncture sepsis model also showed a lack
of survival benefit of mitochondrial antioxidants [51]. Whether the
apparent contradictory effects observed in these previous studies can be
attributed to the specific model of sepsis, the animal species used, or the
magnitude of the sepsis insult is unclear. Genetic ablation of NADPH
oxidase in p47phox-deficient mice, a major non-mitochondrial source
of ROS, exaggerated LPS-induced NF-κB activation, increased expres-
sion of proinflammatory cytokines in lungs, increased neutrophilic al-
veolitis and sustained greater lung injury compared with wild-type mice
[15]. Of note, 2HOBA derivatives do not scavenge ROS such as super-
oxide and peroxynitrite [8], and, therefore, mito2HOBA will not in-
terfere with cell redox signaling as many antioxidants described pre-
viously [51]. These data suggest potentially diverse roles of ROS in
sepsis and the importance of targeting of specific cells and subcellular
compartments such as mitochondria.
In this work we have tested the potential role of IsoLGs in mi-
tochondrial dysfunction and mortality associated with sepsis using new
mitochondria-targeted IsoLG scavenger mito2HOBA (see graphical
Abstract and Fig. 5 scheme). We suggest that IsoLG can be produced by
multiple enzymatic and non-enzymatic pathways [5,11], and that
scavenging of mitochondrial IsoLG can specifically attenuate mi-
tochondrial dysfunction and cell injury associated with inflammation.
Interestingly, mitochondria-targeted antioxidants MitoQ and MitoE at-
tenuate mitochondrial lipid peroxidation, reduce interleukin-6, im-
prove mitochondrial function and diminish the markers of organ dys-
function in rat model of LPS-induced sepsis [52] which is in line with
pathophysiological role of IsoLG produced by lipid peroxidation in
isoprostane pathway [5]. Our work suggests the potential therapeutic
benefit of specifically targeting mitochondrial IsoLGs.
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